AI Supremacy, De-risking, and Domestic Strain
Record Chinese AI Chip IPO Amid Sanctions Signals Tech Independence Push, While Brussels Mandates Technology Transfer and Forces Supply Chain Diversification.
BLUF
EU Mandates De-risking: The European Commission launched a dual-pronged legislative offensive: tightening foreign investment rules to mandate local workers and technology transfer (FT), and mobilizing the €3 billion ReSourceEU strategy aimed at legally forcing industry diversification away from critical Chinese raw material dependency (The Guardian).
Domestic Strain Deepens: Despite outward confidence, China’s internal economy faces acute financial trouble, evidenced by slumping Fixed Asset Investment (FAI) reaching historic two-decade lows (MERICS China Essentials) and overall local government debt reaching an estimated 134 trillion yuan ($18.9 trillion) (Nikkei).
The Quick Take
The week’s news reveals the persistent gap between China’s assertive global image and its troubled domestic foundations. Externally, China’s confidence is bolstered by its ability to withstand US trade pressure, coupled with its use of critical mineral leverage to deter EU de-risking efforts (MERICS China Essentials). Simultaneously, the country is achieving major technological milestones, evidenced by the biotech sector’s rapid global ascension and the frenzy surrounding domestic AI chip IPOs (The Economist, Bloomberg).
Yet, this confidence masks serious internal headwinds. Fixed Asset Investment (FAI), the historical engine of Chinese growth, slumped 12% year-on-year through October, reaching lows comparable only to pandemic years. This downturn is structurally linked to the crisis in local public finances, where local government bonds are primarily being issued for refinancing rather than new investment due to the persistent property slump (Nikkei). The party’s uncompromising prioritization of strategic industrial capacity over welfare and household income growth means the burden of slowing growth and high youth unemployment (around 17%) will fall heavily on ordinary citizens, jeopardizing the core promise of "common prosperity" (MERICS China Essentials).
Headlines
1. China’s AI Chip IPO Hits Record High Amid Sanctions, Driving Tech Supremacy Narrative
Story: Moore Threads Technology Co., a major Chinese AI chipmaker founded by a former Nvidia executive, saw its shares skyrocket 425% in its Shanghai trading debut after raising 8 billion yuan ($1.13 billion) (Bloomberg, FT). This surge marked the largest first-day gain for a major IPO since China’s 2019 market reforms. The Beijing-based company was added to the US Entity List in October 2023, cutting off its access to key manufacturers like TSMC (FT). Despite being loss-making and facing technological setbacks, investor enthusiasm remains exceptionally high, betting on Beijing's accelerated push for technological independence (FT). Experts surveyed anticipate China will make "very major" progress in Artificial Intelligence in 2026 (MERICS China Forecast 2026).
Why it matters for China–EU economic or political relations: This market behavior signals that strategic capital is committed to nurturing domestic champions designed to replace Western suppliers, intensifying the competitive pressure on EU tech sectors (FT, Nikkei). The company’s trajectory—designing GPUs initially for gaming but pivoting to AI accelerators for large language models—mirrors Nvidia's path, confirming China's strategic focus.
2. Brussels Unveils Dual Policy to Demand Tech Transfer and De-risk Critical Supply Chains
Story: The EU is planning to tighten its foreign investment rules, a series of proposals expected next month, intended to ensure that Chinese companies setting up within the bloc contribute meaningful benefits, such as recruiting local workers and transferring technological know-how in sensitive sectors like batteries (FT). This policy directly targets large Chinese FDI projects, exemplified by CATL’s €4.1 billion LFP battery plant joint venture with Stellantis in Spain, where CATL plans to bring 2,000 Chinese workers (FT, Technode). Industry Commissioner Stéphane Séjourné explicitly stated that he prefers using Foreign Direct Investment (FDI) conditionality over tariffs to protect the market (FT). Simultaneously, the Commission unveiled the €3 billion ReSourceEU strategy to reduce dependency on China for critical raw materials (The Guardian). Séjourné warned that if industry doesn't diversify its sourcing, the Commission reserves the right to introduce legislation that would legally oblige European companies to diversify a certain percentage of their supplies. Currently, the EU buys about 20,000 tonnes of permanent magnets annually, with "17,000 to 18,000" tonnes originating from China.
Why it matters for China–EU economic or political relations: The EU is shifting from a passive open-market stance to one of strategic conditionality, directly addressing fears that Chinese FDI is simply a way to circumvent future tariffs and foster European industrial dependence. This legislative shift (expected to be proposed on December 10) aims to largely reduce the "race to the bottom" among European countries vying to attract FDI with lax regulation.
3. Chinese Biotech Accelerates Global Licensing, Challenging Western Pharma Dominance
Story: China is quickly becoming a global leader in new drug development, having run about a third of the world’s clinical trials last year—a major leap from just 5% a decade ago (The Economist). Western "big pharma" firms are increasingly turning to China to fill gaps caused by massive upcoming patent expirations, where drugs generating over $300bn in revenue will lose protection by 2030. Evidence of this dependency is mounting: Pfizer agreed to pay $1.25 billion to 3SBio, and GlaxoSmithKline struck a $500 million deal with Hengrui for licensing experimental drugs. This year, nearly a third of all global licensing agreements signed by big pharma were with Chinese firms, four times the share seen in 2021. China's pharmaceutical overhaul streamlined approval times for human trials from 501 days to just 87, speeding up new drug output. Chinese firms are now moving beyond "fast followers" to create "first-in-class" medicines, focusing heavily on critical areas like cancer and new weight-loss drugs (The Economist).
Why it matters for China–EU economic or political relations: This shift creates dependency risk for European patients and drugmakers on Chinese innovation for cutting-edge treatments. The speed, scale, and low cost of China's human trials offer a significant competitive edge. However, geopolitical concerns persist, especially regarding data privacy and the FDA’s strict approach to drugs based solely on China-only trials.
4. China Pushes ‘Green Minerals’ Alliance to Consolidate Global Rare Earths Chokehold
Story: Chinese Premier Li Qiang advocated for an "international economic and trade co-operation initiative on green minerals" at the G20 leaders summit in South Africa (FT). This alliance, involving at least 19 developing nations like Zimbabwe and Nigeria, aims to consolidate China’s dominance over critical minerals like rare earths, which are vital for modern technology supply chains. This move directly counters US efforts to build its own critical mineral supply chain alliances to curb China’s resource imports. Beijing is keen to build ties with resource-rich developing countries to better safeguard their interests.
Why it matters for China–EU economic or political relations: China is explicitly using its control over minerals as economic leverage, previously implementing export licenses for rare earths during trade tensions. Premier Li's initiative is intended to reinforce this global chokehold, which the MERICS analysis notes is used by Beijing to deter external pressure like the EU's de-risking agenda (MERICS China Essentials). The EU has responded by mobilizing funds and threatening legislation to force industries to diversify away from China-dominated supply chains (The Guardian).
Graph
The bar chart above vividly illustrates the intense investor appetite for Chinese technological independence. On its Shanghai trading debut, loss-making Moore Threads Technology Co. reached a staggering Price-to-Sales (P/S) ratio of 123x, a massive premium that is over four times higher than the P/S ratio of its global peer, Nvidia (30x). This valuation gap, coupled with the company's 425% first-day surge, signals a high-stakes financial commitment by strategic capital to nurturing domestic AI champions and insulating them from US competition.
Quote
We hope the German side will adhere to a rational and pragmatic China policy, rule out interference and pressure, focus on shared interests and consolidate the foundation for cooperation,
Premier Li Qiang’s direct remarks to German Chancellor Friedrich Merz during their meeting on the G20 sidelines signaled Beijing’s determined diplomatic effort to stabilize bilateral ties after months of strain, including Germany’s decision to ban Chinese telecoms suppliers like Huawei from its future 6G network due to security reasons. Li suggested cooperating in emerging fields like new energy and intelligent driving. Furthermore, Li urged Berlin to encourage the EU to view China-EU relations with a "broader perspective" and adhere to its "partnership positioning" with China (SCMP).
What to Watch Next Week
EU Foreign Investment Rules Proposal: The European Commission is scheduled to propose tighter foreign investment rules on December 10. This proposal is crucial as it will specify criteria for foreign investors, likely affecting Chinese firms, regarding technology transfer and local content requirements in key sectors like electric vehicle batteries (FT).
Hainan Free Trade Port (FTP) Official Launch: On December 18, China’s southernmost province, Hainan, is set to officially launch independent customs operations and a major expansion of duty-free imports (Nikkei). This policy move, marked on the anniversary of Deng Xiaoping’s "Reform and Opening Up," will serve as a large-scale litmus test for China's liberalization ambitions amidst global trade turmoil.